What are we trying to prevent in Alzheimer disease?

What are we trying to prevent in Alzheimer disease? Dialogues Clin Neurosci. 2019 Mar;21(1):27-34 Authors: Jessen F Abstract Within aging societies, the number of individuals suffering from Alzheimer disease (AD) is constistently increasing. This is paralleled by intense research aimed at improving treatment options and potentially even fostering effective prevention. The discussion on relevant outcomes of such interventions is ongoing. Here, different types of currently applied outcomes in the treatment of AD at the dementia stage, but also at the pre-dementia stages of mild cognitive impairment (MCI) and asymptomatic preclinical AD are discussed. Regulatory agencies require effects on the clinical measures of cognition and function. In novel disease-modifying therapy trials, biological markers are used as secondary and exploratory outcomes. Additional outcomes of great relevance for the individual patients are neuropsychiatric symptoms, quality of life, and goal attainment. In addition, costs and cost-benefit ratios are of interest for the reimbursement of interventions. PMID: 31607778 [PubMed - in process]
Source: Dialogues in Clinical Neuroscience - Category: Neuroscience Tags: Dialogues Clin Neurosci Source Type: research

Related Links:

DEMENTIA is a progressive neurological condition that mainly affects people over the of 65, although it is not a natural part of ageing. Spotting the early warning signs is key to maintaining quality of life for as long as possible. A recent study suggests that Alzheimer ’s disease, the most common form of dementia, can be signalled by a change in your eyes.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D Abstract INTRODUCTION: We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild-to-moderate probable Alzheimer's disease (AD) dementia. METHODS: Randomized, double-blind, 4-week trial of suvorexant 10 mg (could be increased to 20 mg based on clinical response) or placebo in patients who met clinical diagnostic criteria for both probable AD dementia and insomnia. Sleep was assessed by overnight polysomnography in a sleep laboratory. The primar...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.
Source: Acta Neuropathologica - Category: Neurology Source Type: research
CONCLUSIONS: ¹⁸F-FC119S PET provides high sensitivity and specificity in detecting AD and therefore may be considered a useful diagnostic tool for AD. PMID: 31942769 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
Purpose of review The incidence of Alzheimer's disease is increasing. Premortem diagnosis of Alzheimer's disease is now possible but require invasive and expensive testing such as PET amyloid beta binding and/or spinal fluid amyloid beta levels. There is a great need for minimally invasive and inexpensive biomarkers to allow for early diagnosis and intervention. Recent findings There has been a large volume of literature assessing ocular biomarkers for Alzheimer's disease. Much of the research to date has significant limitations, including sample size, variable diagnostic criteria for Alzheimer's disease, lack of biom...
Source: Current Opinion in Neurology - Category: Neurology Tags: NEURO-OPHTHALMOLOGY: Edited by Heather E. Moss Source Type: research
In conclusion, our study demonstrated that β-asarone can inhibit Aβ, and this effect may occur by promoting autophagy in a cell model of AD.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This report calls on government to invest in six priority research areas, which will help to deliver a life-changing treatment for dementia by doubling research funding and speeding up trials for new treatments.ReportAlzheimer's Research UK - press release
Source: Health Management Specialist Library - Category: UK Health Authors: Tags: Mental Health Source Type: blogs
CONCLUSIONS: The type and characteristics of CS exercises have an impact on the engagement level of AD patients with mild to moderate dementia. Further studies are necessary to better understand which characteristics of the exercises affect the engagement of the patient according to their particularities. This kind of study may help the design of CS sessions and improve the results obtained. PMID: 31940610 [PubMed - as supplied by publisher]
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research
Authors: Sittler MC, Meichsner F, Wilz G Abstract The present study examined the factor structure of a German questionnaire version of the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD), which originally assesses behavioral disturbances in people with dementia independent from cognitive symptoms in a clinical interview with a caregiver. The 7-factor structure of the interview version of the BEHAVE-AD (i. e., Paranoid and Delusional Ideation, Hallucinations, Activity Disturbances, Aggressiveness, Diurnal Rhythm Disturbances, Affective Disturbances, Anxieties and Phobias) could not be confirmed ...
Source: PPmP Psychotherapie Psychosomatik Medizinische Psychologie - Category: Psychiatry & Psychology Tags: Psychother Psychosom Med Psychol Source Type: research
Publication date: Available online 14 January 2020Source: NeuroImage: ClinicalAuthor(s): Kathryn M. Broadhouse, Maria Fiatarone Singh, Chao Suo, Nicola Gates, Wei Wen, Henry Brodaty, Nidhi Jain, Guy C. Wilson, Jacinda Meiklejohn, Nalin Singh, Bernhard T. Baune, Michael Baker, Nasim Foroughi, Yi Wang, Nicole Kochan, Kevin Ashton, Matt Brown, Zhixiu Li, Yorgi Mavros, Perminder S. SachdevABSTRACTDementia affects 47 million individuals worldwide, and assuming the status quo is projected to rise to 150 million by 2050. Prevention of age-related cognitive impairment in older persons with lifestyle interventions continues to garn...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
More News: Alzheimer's | Brain | Dementia | Neurology | Neuroscience